SEARCH

SEARCH BY CITATION

References

  • Ando K., Takei N., Matsumoto H., Iyo M., Isoda H. and Mori N. (2002) Neural damage in the lenticular nucleus linked with tardive dyskinesia in schizophrenia: a preliminary study using proton magnetic resonance spectroscopy. Schizophr. Res. 57, 273279.
  • Aoyama N., Théberge J., Drost D. J. et al. (2011) Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br. J. Psychiatry 198, 448456.
  • Auer D. P., Wilke M., Grabner A., Heidenreich J. O., Bronisch T. and Wetter T. C. (2001) Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. Schizophr. Res. 52, 8799.
  • Aydin K., Ucok A. and Cakir S. (2007) Quantitative proton MR spectroscopy findings in the corpus callosum of patients with schizophrenia suggest callosal disconnection. AJNR Am. J. Neuroradiol. 28, 19681974.
  • Aydin K., Ucok A. and Guler J. (2008) Altered metabolic integrity of corpus callosum among individuals at ultra high risk of schizophrenia and first-episode patients. Biol. Psychiatry 64, 750757.
  • Barker P. B. (2001) N-acetyl aspartate - a neuronal marker? Ann. Neurol. 49, 423424.
  • Bartha R., Drost D. J. and Williamson P. C. (1999) Factors affecting the quantification of short echo in-vivo 1H MR spectra: prior knowledge, peak elimination, and filtering. NMR Biomed. 12, 205216.
  • Basoglu C., Cetin M., Oner O., Ebrinc S., Semiz U. B., Kandilcioglu H., Silit E. and Kizilkaya E. (2006) Comparison of right thalamus and temporal cortex metabolite levels of drug-naive first-episode psychotic and chronic schizophrenia in patients. Turk Psikiyatri Derg. 17, 8591.
  • Berger G. E., Wood S. J., Wellard R. M. et al. (2008) Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology 33, 24672473.
  • Bertolino A. and Weinberger D. R. (1999) Proton magnetic resonance spectroscopy in schizophrenia. Eur. J. Radiol. 30, 132141.
  • Bertolino A., Callicott J. H., Mattay V. S., Weidenhammer K. M., Rakow R., Egan M. F. and Weinberger D. R. (2001) The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol. Psychiatry 49, 3946.
  • Bertolino A., Sciota D., Brudaglio F. et al. (2003) Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. Am. J. Psychiatry 160, 483489.
  • Blatter D. D., Bigler E. D., Gale S. D., Johnson S. C., Anderson C. V., Burnett B. M., Parker N., Kurth S. and Horn S. D. (1995) Quantitative volumetric analysis of brain MR: normative database spanning 5 decades of life. AJNR Am. J. Neuroradiol. 16, 241251.
  • Block W., Bayer T. A., Tepest R. et al. (2000) Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. Neurosci. Lett. 289, 147151.
  • Bloemen O. J., Gleich T., de Koning M. B., da Silva Alvis F., de Haan L., Linszen D. H., Booij J. and van Amelsvoort T. A. (2011) Hippocampal glutamate levels and striatal dopamine D(2/3) receptor occupancy in subjects at ultra high risk of psychosis. Biol. Psychiatry 70, e1e2; author reply e3.
  • Bogner W., Gruber S., Doelken M. et al. (2010) In vivo quantification of intracerebral GABA by single-voxel (1)H-MRS-How reproducible are the results? Eur. J. Radiol. 73, 526531.
  • Braus D. F., Ende G., Weber-Fahr W., Demirakca T., Tost H. and Henn F. A. (2002) Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia. Eur. Neuropsychopharmacol. 12, 145152.
  • Brief E. E., Moll R., Li D. K. and Mackay A. L. (2009) Absolute metabolite concentrations calibrated using the total water signal in brain (1)H MRS. NMR Biomed. 22, 349354.
  • Bustillo J. R., Rowland L. M., Jung R., Brooks W. M., Qualls C., Hammond R., Hart B. and Lauriello J. (2008) Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia.Neuropsychopharmacology: official publication of the American College of. Neuropsychopharmacology 33, 24562466.
  • Bustillo J. R., Rowland L. M., Mullins P., Jung R., Chen H., Qualls C., Hammond R., Brooks W. M. and Lauriello J. (2010) 1H-MRS at 4 tesla in minimally treated early schizophrenia. Mol. Psychiatry 15, 629636.
  • Bustillo J. R., Chen H., Gasparovic C., Mullins P., Caprihan A., Qualls C., Apfeldorf W., Lauriello J. and Posse S. (2010) Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol. Psychiatry 69, 1927.
  • Byne W., Hazlett E. A., Buchsbaum M. S. and Kemether E. (2009) The thalamus and schizophrenia: current status of research. Acta Neuropathol. 117, 347368.
  • Callicott J. H., Egan M. F., Bertolino A., Mattay V. S., Langheim F. J., Frank J. A. and Weinberger D. R. (1998) Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biol. Psychiatry 44, 941950.
  • Callicott J. H., Bertolino A., Egan M. F., Mattay V. S., Langheim F. J. and Weinberger D. R. (2000) Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am. J. Psychiatry 157, 16461651.
  • Callicott J. H., Egan M. F., Mattay V. S., Bertolino A., Bone A. D., Verchinksi B. and Weinberger D. R. (2003) Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am. J. Psychiatry 160, 709719.
  • Canuso C. M. and Pandina G. (2007) Gender and schizophrenia. Psychopharmacol. Bull. 40, 178190.
  • Carlsson A., Waters N. and Carlsson M. L. (1999) Neurotransmitter interactions in schizophrenia-therapeutic implications. Eur. Arch. Psychiatry Clin. Neurosci. 249 (Suppl 4), 3743.
  • Chan R. C., Di X., McAlonan G. M. and Gong Q. Y. (2011) Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression. Schizophr. Bull. 37, 177188.
  • Chang L., Friedman J., Ernst T., Zhong K., Tsopelas N. D. and Davis K. (2007) Brain metabolite abnormalities in the WM of elderly schizophrenic subjects: implication for glial dysfunction. Biol. Psychiatry 62, 13961404.
  • Chen X., Sachdev P. S., Wen W. and Anstey K. J. (2007) Sex differences in regional gray matter in healthy individuals aged 44-48 years: a voxel-based morphometric study. NeuroImage 36, 691699.
  • Clark J. B. (1998) N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev. Neurosci. 20, 271276.
  • Cosgrove K. P., Mazure C. M. and Staley J. K. (2007) Evolving knowledge of sex differences in brain structure, function, and chemistry. Biol. Psychiatry 62, 847855.
  • Csernansky J. G., Schindler M. K., Splinter N. R. et al. (2004) Abnormalities of thalamic volume and shape in schizophrenia. Am. J. Psychiatry 161, 896902.
  • Dager S. R., Corrigan N. M., Richards T. L. and Posse S. (2008) Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders. Top. Magn. Reson. Imaging 19, 8196.
  • Deicken R. F., Johnson C., Eliaz Y. and Schuff N. (2000) Reduced concentrations of thalamic N-acetylaspartate in male patients with schizophrenia. Am. J. Psychiatry 157, 644647.
  • Deicken R. F., Feiwell R., Schuff N. and Soher B. (2001) Evidence for altered cerebellar vermis neuronal integrity in schizophrenia. Psychiatry Res. 107, 125134.
  • Delamillieure P., Fernandez J., Constans J. M. et al. (2000) Proton magnetic resonance spectroscopy of the medial prefrontal cortex in patients with deficit schizophrenia: preliminary report. Am. J. Psychiatry 157, 641643.
  • Do K. Q., Trabesinger A. H., Kirsten-Kruger M., Lauer C. J., Dydak U., Hell D., Holsboer F., Boesiger P. and Cuenod M. (2000) Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci. 12, 37213728.
  • Drost D. J., Riddle W. R. and Clarke G. D. (2002) Proton magnetic resonance spectroscopy in the brain: report of AAPM MR Task Group #9. Med. Phys. 29, 21772197.
  • Ellison-Wright I. and Bullmore E. (2009) Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr. Res. 108, 310.
  • van Elst L. T., Valerius G., Büchert M., Thiel T., Rüsch N., Bubl E., Hennig J., Ebert D. and Olbrich H. M. (2005) Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol. Psychiatry 1, 724730.
  • Ende G., Braus D. F., Walter S., Weber-Fahr W., Soher B., Maudsley A. A. and Henn F. A. (2000) Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. Schizophr. Res. 41, 389395.
  • Fannon D., Simmons A., Tennakoon L., O'Ceallaigh S., Sumich A., Doku V., Shew C. and Sharma T. (2003) Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia. Biol. Psychiatry 54, 587598.
  • Farber N. B. (2003) The NMDA receptor hypofunction model of psychosis. Ann. N. Y. Acad. Sci. 1003, 119130.
  • Fornito A., Yucel M. and Pantelis C. (2009) Reconciling neuroimaging and neuropathological findings in schizophrenia and bipolar disorder. Curr. Opin. Psychiatry 22, 312319.
  • Frahm J., Bruhn H., Gyngell M. L., Merboldt K. D., Hänicke W. and Sauter R. (1989) Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn. Reson. Med. 9, 7993.
  • de la Fuente-Sandoval C., Favila R., Alvarado P., Leon-Ortiz P., Diaz-Galvis L., Amezcua C., Garcia-Munoz E. and Graff-Guerrero A. (2009) Glutamate increase in the associative striatum in schizophrenia: a longitudinal magnetic resonance spectroscopy preliminary study. Gac. Med. Mex. 145, 109113.
  • de la Fuente-Sandoval C., Leon-Ortiz P., Favila R., Stephano S., Mamo D., Ramirez-Bermudez J. and Graff-Guerrero A. (2011) Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis.. Neuropsychopharmacology 36, 17811791.
  • Fujiwara H., Shimizu M., Hirao K., Miyata J., Namiki C., Sawamoto N., Fukuyama H., Hayashi T. and Murai T. (2008) Female specific anterior cingulate abnormality and its association with empathic disability in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 17281734.
  • Fukuzako H. (2000) Heritability heightens brain metabolite differences in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 12, 9597.
  • Fusar-Poli P., Perez J., Broome M. et al. (2007) Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 31, 465484.
  • Fusar-Poli P., Howes O., Valli I., Allen P., Broome M., Grasby P. and McGuire P. (2009) Multimodal functional imaging investigation before and after the onset of psychosis. Int. J. Neuropsychopharmacol. 12, 579581.
  • Galinska B., Szulc A., Tarasow E., Kubas B., Dzienis W., Czernikiewicz A. and Walecki J. (2009) Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia. Med. Sci. Monit. 15, CR82CR88.
  • Gillies R. J. (1992) Nuclear magnetic resonance and its applications to physiological problems. Annu. Rev. Physiol. 54, 733748.
  • Gimenez M., Junque C., Perez M., Vendrell P., Baeza I., Salamero M., Mercader J. M. and Bernardo M. (2003) Basal ganglia N-acetylaspartate correlates with the performance in the procedural task ‘Tower of Hanoi’ of neuroleptic-naive schizophrenic patients. Neurosci. Lett. 347, 97100.
  • Goto N., Yoshimura R., Moriya J. et al. (2009) Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. Schizophr. Res. 112, 192193.
  • Goto N., Yoshimura R., Kakeda S. et al. (2010) No alterations of brain GABA after 6 months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 14801483.
  • Goto N., Yoshimura R., Kakeda S. et al. (2011) Comparison of brain N-acetylaspartate levels and serum brain-derived neurotrophic factor (BDNF) levels between patients with first-episode schizophrenia psychosis and healthy controls. Eur. Psychiatry 26, 5763.
  • Govindaraju V., Young K. and Maudsley A. A. (2000) Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 13, 129153.
  • Gur R. C., Turetsky B. I., Matsui M., Yan M., Bilker W., Hughett P. and Gur R. E. (1999) Sex differences in brain gray and white matter in healthy young adults: correlations with cognitive performance. J. Neurosci. 19, 40654072.
  • Hammen T. and Stefan H. (2004) (1)H MR spectroscopy. Methods and applications in diagnosis and assessment of surgical and conservative treatment strategies in epilepsies. Nervenarzt 75, 970983.
  • Hardy C. J., Tal A., Babb J. S., Perry N. N., Messinger J. W., Antonius D., Malaspina D. and Gonen O. (2011) Multivoxel proton MR spectroscopy used to distinguish anterior cingulate metabolic abnormalities in patients with schizophrenia. Radiology 261, 542550.
  • Harms M. P., Wang L., Mamah D., Barch D. M., Thompson P. A. and Csernansky J. G. (2007) Thalamic shape abnormalities in individuals with schizophrenia and their nonpsychotic siblings. J. Neurosci. 27, 1383513842.
  • Hasan A., Wobrock T., Falkai P. et al. (2011) Hippocampal integrity and neurocognition in first-episode schizophrenia: a multidimensional study. World J. Biol. Psychiatry [Epub ahead of print].
  • He Z. L., Deng W., Li M. L., Chen Z. F., Collier D. A., Ma X. and Li T. (2012) Detection of metabolites in the white matter of frontal lobes and hippocampus with proton in first-episode treatment-naive schizophrenia patients. Early Interv. Psychiatry 6, 166175.
  • Hirvonen J., van Erp T. G., Huttunen J. et al. (2005) Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch. Gen. Psychiatry 62, 371378.
  • Honea R., Crow T. J., Passingham D. and Mackay C. E. (2005) Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am. J. Psychiatry 162, 22332245.
  • Hurd R., Sailasuta N., Srinivasan R., Vigneron D. B., Pelletier D. and Nelson S. J. (2004) Measurement of brain glutamate using TE-averaged PRESS at 3T. Magn. Reson. Med. 51, 435440.
  • Inglese M., Spindler M., Babb J. S., Sunenshine P., Law M. and Gonen O. (2006) Field, coil, and echo-time influence on sensitivity and reproducibility of brain proton MR spectroscopy. AJNR Am. J. Neuroradiol. 27, 684688.
  • Jakary A., Vinogradov S., Feiwell R. and Deicken R. F. (2005) N-acetylaspartate reductions in the mediodorsal and anterior thalamus in men with schizophrenia verified by tissue volume corrected proton MRSI. Schizophr. Res. 76, 173185.
  • Jansen J. F., Backes W. H., Nicolay K. and Kooi M. E. (2006) 1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology 240, 318332.
  • Jessen F., Scherk H., Traber F. et al. (2006) Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophr. Res. 87, 8188.
  • Jessen F., Fingerhut N., Sprinkart A. M. et al. (2013) N-acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophrenia. Schizophr. Bull. 39, 197205.
  • Kapur S., Mizrahi R. and Li M. (2005) From dopamine to salience to psychosis–linking biology, pharmacology and phenomenology of psychosis. Schizophr. Res. 79, 5968.
  • Kegeles L. S., Shungu D. C., Anjilvel S. et al. (2000) Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. Psychiatry Res. 98, 163175.
  • Kegeles L. S., Mao X., Stanford A. D. et al. (2012) Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 69, 449459.
  • Klar A. A., Ballmaier M., Leopold K., Hake I., Schaefer M., Bruhl R., Schubert F. and Gallinat J. (2010) Interaction of hippocampal volume and N-acetylaspartate concentration deficits in schizophrenia: a combined MRI and 1H-MRS study. NeuroImage 53, 5157.
  • Kreis R. (2004) Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts. NMR Biomed. 17, 361381.
  • Kreis R., Ernst T. and Ross B. D. (1993) Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn. Reson. Med. 30, 424437.
  • Kreis R., Slotboom J., Hofmann L. and Boesch C. (2005) Integrated data acquisition and processing to determine metabolite contents, relaxation times, and macromolecule baseline in single examinations of individual subjects. Magn. Reson. Med. 54, 761768.
  • Li B. S., Wang H. and Gonen O. (2003) Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. Magn. Reson. Imaging 21, 923928.
  • Lui S., Deng W., Huang X. et al. (2009) Neuroanatomical differences between familial and sporadic schizophrenia and their parents: an optimized voxel-based morphometry study. Psychiatry Res. 171, 7181.
  • Lutkenhoff E. S., van Erp T. G., Thomas M. A. et al. (2010) Proton MRS in twin pairs discordant for schizophrenia. Mol. Psychiatry 15, 308318.
  • Mamah D., Harms M. P., Wang L., Barch D., Thompson P., Kim J., Miller M. I. and Csernansky J. G. (2008) Basal ganglia shape abnormalities in the unaffected siblings of schizophrenia patients. Biol. Psychiatry 64, 111120.
  • Marshall I., Wardlaw J., Cannon J., Slattery J. and Sellar R. J. (1996) Reproducibility of metabolite peak areas in 1H MRS of brain. Magn. Reson. Imaging 14, 281292.
  • Martinez-Granados B., Brotons O., Martinez-Bisbal M. C., Celda B., Marti-Bonmati L., Aguilar E. J., Gonzalez J. C. and Sanjuan J. (2008) Spectroscopic metabolomic abnormalities in the thalamus related to auditory hallucinations in patients with schizophrenia. Schizophr. Res. 104, 1322.
  • Matsuzawa D., Obata T., Shirayama Y. et al. (2008) Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One 3, e1944.
  • Maudsley A. A., Domenig C., Govind V., Darkazanli A., Studholme C., Arheart K. and Bloomer C. (2009) Mapping of brain metabolite distributions by volumetric proton MR spectroscopic imaging (MRSI). Magn. Reson. Med. 61, 548559.
  • Michaelis T., Merboldt K. D., Bruhn H., Hanicke W. and Frahm J. (1993) Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology 187, 219227.
  • Miyaoka T., Yasukawa R., Mizuno S., Sukegawa T., Inagaki T., Horiguchi J., Seno H., Oda K. and Kitagaki H. (2005) Proton magnetic resonance spectroscopy (1H-MRS) of hippocampus, basal ganglia, and vermis of cerebellum in schizophrenia associated with idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). J. Psychiatr. Res. 39, 2934.
  • Moffett J. R. and Namboodiri M. A. (1995) Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. J. Neurocytol. 24, 409433.
  • Molina V., Sanchez J., Reig S. et al. (2005) N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration. Schizophr. Res. 73, 209219.
  • Moore C. M., Bonello C. M., Sherwood A. R., Cohen B. M., Renshaw P. F. and Yurgulen-Todd D. A. (2002) Mesial temporal lobe Cho to Cr(PCr) ratio asymmetry in chronic schizophrenics. Schizophr. Res. 57, 3542.
  • Morche S. (2005) Single-Voxel- versus Multi-Voxel Protonen-MR-Spektroskopie bei verschiedenen intrakraniellen Läsionen. University Würzburg, Würzburg.
  • Moreno D., Burdalo M., Reig S., Parellada M., Zabala A., Desco M., Baca-Baldomero E. and Arango C. (2005) Structural neuroimaging in adolescents with a first psychotic episode. J. Am. Acad. Child Adolesc. Psychiatry 44, 11511157.
  • Narr K. L., Thompson P. M., Sharma T. et al. (2001) Three-dimensional mapping of temporo-limbic regions and the lateral ventricles in schizophrenia: gender effects. Biol. Psychiatry 50, 8497.
  • Novotny E. J. Jr, Fulbright R. K., Pearl P. L., Gibson K. M. and Rothman D. L. (2003) Magnetic resonance spectroscopy of neurotransmitters in human brain. Ann. Neurol. 54 (Suppl 6), S25S31.
  • Ohara K., Isoda H., Suzuki Y., Takehara Y., Ochiai M., Takeda H., Hattori K., Igarashi Y. and Ohara K. (2000) Proton magnetic resonance spectroscopy of lenticular nuclei in simple schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 24, 507519.
  • Ohrmann P., Siegmund A., Suslow T. et al. (2007) Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J. Psychiatr. Res. 41, 625634.
  • Ohrmann P., Kugel H., Bauer J. et al. (2008) Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy. Schizophr. Res. 106, 156163.
  • Olbrich H. M., Valerius G., Rusch N., Buchert M., Thiel T., Hennig J., Ebert D. and Van Elst L. T. (2008) Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J. Biol. Psychiatry 9, 5963.
  • Omori M., Murata T., Kimura H., Koshimoto Y., Kado H., Ishimori Y., Ito H. and Wada Y. (2000) Thalamic abnormalities in patients with schizophrenia revealed by proton magnetic resonance spectroscopy. Psychiatry Res. 98, 155162.
  • O'Neill J., Levitt J., Caplan R., Asarnow R., McCracken J. T., Toga A. W. and Alger J. R. (2004) 1H MRSI evidence of metabolic abnormalities in childhood-onset schizophrenia. NeuroImage 21, 17811789.
  • Ongur D., Prescot A. P., Jensen J. E., Cohen B. M. and Renshaw P. F. (2009) Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res. 172, 4448.
  • Ongur D., Prescot A. P., Jensen J. E., Rouse E. D., Cohen B. M., Renshaw P. F. and Olson D. P. (2010a) T2 relaxation time abnormalities in bipolar disorder and schizophrenia. Magn. Reson. Med. 63, 18.
  • Ongur D., Prescot A. P., McCarthy J., Cohen B. M. and Renshaw P. F. (2010b) Elevated gamma-aminobutyric acid levels in chronic schizophrenia. Biol. Psychiatry 68, 667670.
  • Ota M, Ishikawa M, Sato N, Hori H, Sasayama D, Hattori K, Teraishi T, Nakata Y and Kunugi H. (2012) Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation. Acta Psychiatr. Scand. 126, 7278.
  • Pfefferbaum A., Adalsteinsson E., Spielman D., Sullivan E. V. and Lim K. O. (1999) In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn. Reson. Med. 41, 276284.
  • Pfeuffer J., Tkac I., Provencher S. W. and Gruetter R. (1999) Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. J. Magn. Reson. 141, 104120.
  • Pouwels P. J. and Frahm J. (1998) Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn. Reson. Med. 39, 5360.
  • Purdon S. E., Valiakalayil A., Hanstock C. C., Seres P. and Tibbo P. (2008) Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia. Schizophr. Res. 99, 218224.
  • Reid M. A., Stoeckel L. E., White D. M., Avsar K. B., Bolding M. S., Akella N. S., Knowlton R. C., den Hollander J. A. and Lahti A. C. (2010) Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol. Psychiatry 68, 625633.
  • Reig S., Moreno C., Moreno D., Burdalo M., Janssen J., Parellada M., Zabala A., Desco M. and Arango C. (2009) Progression of brain volume changes in adolescent-onset psychosis. Schizophr. Bull. 35, 233243.
  • Reiss A. L., Abrams M. T., Singer H. S., Ross J. L. and Denckla M. B. (1996) Brain development, gender and IQ in children. A volumetric imaging study. Brain 119 (Pt 5), 17631774.
  • Rothermundt M., Ohrmann P., Abel S. et al. (2007) Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 361364.
  • Rothman D. L., Sibson N. R., Hyder F., Shen J., Behar K. L. and Shulman R. G. (1999) In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 11651177.
  • Rowland L., Bustillo J. R. and Lauriello J. (2001) Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia. Semin. Clin. Neuropsychiatry 6, 121130.
  • Rowland L. M., Spieker E. A., Francis A., Barker P. B., Carpenter W. T. and Buchanan R. W. (2009) White matter alterations in deficit schizophrenia. Neuropsychopharmacology: official publication of the American College of. Neuropsychopharmacology 34, 15141522.
  • Rusch N., Tebartz van Elst L., Valerius G., Buchert M., Thiel T., Ebert D., Hennig J. and Olbrich H. M. (2008) Neurochemical and structural correlates of executive dysfunction in schizophrenia. Schizophr. Res. 99, 155163.
  • Sanches R. F., Crippa J. A., Hallak J. E., Araujo D. and Zuardi A. W. (2004) Proton magnetic resonance spectroscopy of the frontal lobe in schizophrenics: a critical review of the methodology. Rev. Hosp. Clin. Fac. Med. Sao Paulo 59, 145152.
  • Sanches R. F., Crippa J. A., Hallak J. E., de Sousa J. P., Araujo D., Santos A. C. and Zuardi A. W. (2008) Proton magnetic resonance spectroscopy of the frontal, cingulate and perirolandic cortices and its relationship to skin conductance in patients with schizophrenia. Braz. J. Med. Biol. Res. 41, 11321141.
  • Seamans J. K. and Yang C. R. (2004) The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog. Neurobiol. 74, 158.
  • Shimizu E., Hashimoto K., Ochi S. et al. (2007) Posterior cingulate gyrus metabolic changes in chronic schizophrenia with generalized cognitive deficits. J. Psychiatr. Res. 41, 4956.
  • Sigmundsson T., Maier M., Toone B. K., Williams S. C., Simmons A., Greenwood K. and Ron M. A. (2003) Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr. Res. 64, 6371.
  • Simmons M. L., Frondoza C. G. and Coyle J. T. (1991) Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45, 3745.
  • Stanley J. A., Williamson P. C., Drost D. J., Rylett R. J., Carr T. J., Malla A. and Thompson R. T. (1996) An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr. Bull. 22, 597609.
  • Stanley J. A., Pettegrew J. W. and Keshavan M. S. (2000) Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings–part I. Biol. Psychiatry 48, 357368.
  • Stanley J. A., Vemulapalli M., Nutche J., Montrose D. M., Sweeney J. A., Pettegrew J. W., MacMaster F. P. and Keshavan M. S. (2007) Reduced N-acetyl-aspartate levels in schizophrenia patients with a younger onset age: a single-voxel 1H spectroscopy study. Schizophr. Res. 93, 2332.
  • Steel R. M., Bastin M. E., McConnell S., Marshall I., Cunningham-Owens D. G., Lawrie S. M., Johnstone E. C. and Best J. J. (2001) Diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (1H MRS) in schizophrenic subjects and normal controls. Psychiatry Res. 106, 161170.
  • Steen R. G., Hamer R. M. and Lieberman J. A. (2005) Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology: official publication of the American College of. Neuropsychopharmacology 30, 19491962.
  • Stone J. M., Day F., Tsagaraki H., Valli I., McLean M. A., Lythgoe D. J., O'Gorman R. L., Barker G. J. and McGuire P. K. (2009) Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol. Psychiatry 66, 533539.
  • Supprian T., Hofmann E., Warmuth-Metz M., Franzek E. and Becker T. (1997) MRI T2 relaxation times of brain regions in schizophrenic patients and control subjects. Psychiatry Res. 75, 173182.
  • Szulc A. G., Tarasow B., Kubas E., Dzienis B., Walecki W., Czernikiewicz J. and A. (2004) Glutamatergic system dysfunction in schizophrenia. A proton magnetic resonance spectroscopy (1H MRS) Study. Pol. J. Radiol. 69, 3336.
  • Szulc A., Galinska B., Tarasow E. et al. (2007) N-acetylaspartate (NAA) levels in selected areas of the brain in patients with chronic schizophrenia treated with typical and atypical neuroleptics: a proton magnetic resonance spectroscopy (1H MRS) study. Med. Sci. Monit. 13 (Suppl 1), 1722.
  • Szulc A., Galinska B., Tarasow E., Waszkiewicz N., Konarzewska B., Poplawska R., Bibulowicz D., Simonienko K. and Walecki J. (2011) Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment. Pharmacopsychiatry 44, 148157.
  • Tamagaki C., Sedvall G. C., Jonsson E. G., Okugawa G., Hall H., Pauli S. and Agartz I. (2005) Altered white matter/gray matter proportions in the striatum of patients with schizophrenia: a volumetric MRI study. Am. J. Psychiatry 162, 23152321.
  • Tang C. Y., Friedman J., Shungu D. et al. (2007) Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls. BMC Psychiatry 7, 25.
  • Tayoshi S., Sumitani S., Taniguchi K. et al. (2009) Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr. Res. 108, 6977.
  • Tayoshi S., Nakataki M., Sumitani S. et al. (2010) GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophr. Res. 117, 8391.
  • Théberge J., Bartha R., Drost D. J. et al. (2002) Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am. J. Psychiatry 159, 19441946.
  • Théberge J., Al-Semaan Y., Williamson P. C., Menon R. S., Neufeld R. W., Rajakumar N., Schaefer B., Densmore M. and Drost D. J. (2003) Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am. J. Psychiatry 160, 22312233.
  • Théberge J., Williamson P. C., Manchanda R., Menon R. S., Neufeld R. W., Densmore M., Williamson K. E. and Drost D. J. (2004) Longitudinal Study of First-Episode Schizophrenia using 4.0T 1H MRS and Voxel-Based Morphometry. Proc. Intl. Soc. Mag. Reson. Med. 11, 523.
  • Théberge J., Jensen J. E. and Rowland L. M. (2007a) Regarding “Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study”. Biol. Psychiatry 61, 12181219; author reply 1219–1220.
  • Théberge J., Williamson K. E., Aoyama N. et al. (2007b) Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br. J. Psychiatry 191, 325334.
  • Tibbo P., Hanstock C., Valiakalayil A. and Allen P. (2004) 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am. J. Psychiatry 161, 11161118.
  • Tkac I., Andersen P., Adriany G., Merkle H., Ugurbil K. and Gruetter R. (2001) In vivo 1H NMR spectroscopy of the human brain at 7 T. Magn. Reson. Med. 46, 451456.
  • Tost H., Alam T. and Meyer-Lindenberg A. (2010) Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes. Neurosci. Biobehav. Rev. 34, 689700.
  • Tunc-Skarka N., Weber-Fahr W., Hoerst M., Meyer-Lindenberg A., Zink M. and Ende G. (2009) MR spectroscopic evaluation of N-acetylaspartate's T2 relaxation time and concentration corroborates white matter abnormalities in schizophrenia. NeuroImage 48, 525531.
  • Urenjak J., Williams S. R., Gadian D. G. and Noble M. (1993) Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J. Neurosci. 13, 981989.
  • Vita A., De Peri L., Silenzi C. and Dieci M. (2006) Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr. Res. 82, 7588.
  • Walter H. (2005) Funktionelle Bildgebung in Psychiatrie und Psychotherapie. Methodische Grundlagen und klinische Anwendungen. Schattauer GmbH, Stuttgart, New York.
  • Watts J., Fowler L., Whitton P. S. and Pearce B. (2005) Release of arginine, glutamate and glutamine in the hippocampus of freely moving rats: Involvement of nitric oxide. Brain Res. Bull. 65, 521528.
  • Weber-Fahr W., Ende G., Braus D. F., Bachert P., Soher B. J., Henn F. A. and Buchel C. (2002) A fully automated method for tissue segmentation and CSF-correction of proton MRSI metabolites corroborates abnormal hippocampal NAA in schizophrenia. NeuroImage 16, 4960.
  • Whittall K. P., MacKay A. L., Graeb D. A., Nugent R. A., Li D. K. and Paty D. W. (1997) In vivo measurement of T2 distributions and water contents in normal human brain. Magn. Reson. Med. 37, 3443.
  • Williamson P., Pelz D., Merskey H., Morrison S., Karlik S., Drost D., Carr T. and Conlon P. (1992) Frontal, temporal, and striatal proton relaxation times in schizophrenic patients and normal comparison subjects. Am. J. Psychiatry 149, 549551.
  • Wobrock T., Scherk H. and Falkai P. (2005) Magnetic resonance spectroscopy in schizophrenia. Possibilities and limitations. Radiologe 45: 124136.
  • Wood S. J., Berger G. E., Wellard R. M., Proffitt T., McConchie M., Velakoulis D., McGorry P. D. and Pantelis C. (2008) A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naive and early-treated first episode psychosis. Schizophr. Res. 102, 163170.
  • Wood S. J., Berger G. E., Wellard R. M., Proffitt T. M., McConchie M., Berk M., McGorry P. D. and Pantelis C. (2009) Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol. Dis. 33, 354357.
  • Woodward N. D., Waldie B., Rogers B., Tibbo P., Seres P. and Purdon S. E. (2009) Abnormal prefrontal cortical activity and connectivity during response selection in first episode psychosis, chronic schizophrenia, and unaffected siblings of individuals with schizophrenia. Schizophr. Res. 109, 182190.
  • Yamasue H., Fukui T., Fukuda R. et al. (2002) 1H-MR spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia. NeuroReport 13, 21332137.
  • Yasukawa R., Miyaoka T., Mizuno S., Inagaki T., Horiguchi J., Oda K. and Kitagaki H. (2005) Proton magnetic resonance spectroscopy of the anterior cingulate gyrus, insular cortex and thalamus in schizophrenia associated with idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). J. Psychiatry Neurosci. 30, 416422.
  • Yoo S. Y., Yeon S., Choi C. H. et al. (2009) Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. Schizophr. Res. 111, 8693.
  • Yoon J. H., Maddock R. J., Rokem A., Silver M. A., Minzenberg M. J., Ragland J. D. and Carter C. S. (2010) GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J. Neurosci. 30, 37773781.
  • Yucel M., Stuart G. W., Maruff P., Velakoulis D., Crowe S. F., Savage G. and Pantelis C. (2001) Hemispheric and gender-related differences in the gross morphology of the anterior cingulate/paracingulate cortex in normal volunteers: an MRI morphometric study. Cereb. Cortex 11, 1725.
  • Yucel M., Lubman D. I., Harrison B. J. et al. (2007) A combined spectroscopic and functional MRI investigation of the dorsal anterior cingulate region in opiate addiction. Mol. Psychiatry 12, 611; 691702.
  • Zaaraoui W., Fleysher L., Fleysher R., Liu S., Soher B. J. and Gonen O. (2007) Human brain-structure resolved T(2) relaxation times of proton metabolites at 3 Tesla. Magn. Reson. Med. 57, 983989.
  • Zabala A., Sanchez-Gonzalez J., Parellada M., Moreno D. M., Reig S., Burdalo M. T., Robles O., Desco M. and Arango C. (2007) Findings of proton magnetic resonance spectometry in the dorsolateral prefrontal cortex in adolescents with first episodes of psychosis. Psychiatry Res. 156, 3342.